VOS Healthcare is a leading provider of stem cell therapy and regenerative medicine services globally. It has a large, loyal customer base and aims to converge all stem cell related services. VOS has achieved strong, consistent financial growth in recent years and has high operating margins due to its recurring revenue model. It is well positioned for continued leadership in the stem cell industry.

1. INVESTOR PRESENTATION

2. Disclaimer
This Investor Presentation has been prepared by VOS HEALTHCARE LLC, USA . For investors, solely for informational
purposes.
The information contained herein has been prepared to assist prospective investors in making their own evaluation of the Company and does no
purport to be all-inclusive or to contain all of the information a prospective or existing investor may desire. In all cases, interested parties should
conduct their own investigation and analysis of the Company and the data set forth in this information. VOS makes no representation or warran
the accuracy or completeness of this information and shall not have any liability for any representations (expressed or implied) regarding informa
contained in, or for any omissions from, this information or any other written or oral communications transmitted to the recipient in the course of
evaluation of the Company.
This Information includes certain statements and estimates provided by the Company with respect to the projected future performance of the
Company. Such statements, estimates and projections reflect various assumptions by management concerning possible anticipated results, whi
assumptions may or may not be correct. No representations are made as to the accuracy of such statements, estimates or projections. Prospec
investors will be expected to have conducted their own due diligence investigation regarding these and all other matters pertinent to investment
Company.
This presentation may contain statements that are not historical facts, referred to as “forward looking statements.” The corporation’s actual futur
results may differ materially from those suggested by such statements, depending on various factors including those described in filings made w
SEC.
2

3. EXECUTIVE SUMMARY AND GROWTH PLATFORM

4. Mission
NaSCFI goal is to be the largest STEM CELL THERAPY AND BANKING services player in the world.
CONVERGENCE
The company’s technology vision is to focus on convergence of all STEM CELL THERAPY and STEM CELL BANKING in a manner that
Patient can seamlessly get treatment or services at door step. . The company intends to do that by designing products and services that
are pioneering and at least a few years ahead of its competition. The company believes that profitability and revenue growth must go hand
in hand.
With no competitors who can match the completeness of its vision or its distinct advantages, NaSCFI is ideally positioned to seize an
enormous “green field” opportunity. Continually cited for the high quality of its offering, NaSCFI has built an outstanding reputation among
a large, impressive customer base. With a strong recurring, Stem Cell therapy as a Therapeutic Cure model, NaSCFI is positioned to be a
leading player in the Healthcare, surely moving towards the disease free world
4

5. VOS HEALTHCARE Introduction
VOS Healthcare Pvt Ltd (the “Company”) was founded in 2011 by VOS Healthcare LLC, USA, a Washington corporation.
VOS Healthcare LLC, USA is a leading provider of Adult Stem cell therapy and Regenerative medicine and Stem Cell Banking
( Cord Blood and Menstrual blood banking). VOS provides therapeutic as well as storing facilities all over the globe. Our
services are ranging from collection, transportation, carrier systems, sterile environment for packaging, laboratory and
centers, Banking of Stem cell along with a solutions storing for variety of period and flexibility of payment all across the globe.
VOS powers multiple exchanges across the world in the field of Autologous Stem cell Production, Differentiations, Newer
research Treatment and Research in Biopharma conducting in excess of $100 billion at the possible sector of business on its
platforms
VOS’s goal is to be the leading backend powerhouse of STEM CELL THERAPY in the world. The Company’s healthcare vision is to
focus on convergence of all possible therapies in Stem cell, processes of Stem Cell Banking, Culturing and Differentiation of the
stem cell, Derivation and Perpetuating in to Tissue Specific Cell, Cell cytometeric counting, Sterile chain and delivery to the
patient all these in a manner such that viability and sterility is maintained and the complete complex function can seamlessly
flow once the collection of Stem cell has been made.
With a recurring revenue base in excess of 75% +, VOS strives to work collaboratively with clients to develop innovative
technology strategies and solutions that address specific business challenges. VOS combines the newest technologies with its
capabilities in distant consulting, Advance Research and Cell therapy design and integration, Franchising and business to meet
the individual needs of patients and with the continuous changes occurring in the diseases grading and presentation and its
treatment.
The Company has its headquarters in Seattle, Washington, and has domestic operations in New Jersey, Pittsburgh. The
Company also has offices in four other countries namely Australia, England, Poland and India. Through its various VOS based
software platforms, VOS employs 300 professionals providing products, support and counselling to thousands of customers on
six continents across 50+ countries.
VOS’s focus on quality has enabled its development unit in India to be awarded Level 5 status of the University of Pittsburgh
Medical Center’s Capability. The Company has received numerous awards and recognition from its Healthcare industry, the
media, and by customers including being ranked very high in the top 100 fastest growing companies in the world
5

6. Summary Highlights
Industry Leadership Opportunity by Leveraging VOS’s Strong Market Presence. The U.S. Healthcare market is a highly fragmented
$360
billion industry. VOS’s innovative Adult Stem cell Therapy and its global reach, positions it as a possible leader in the worldwide Regenerative
Medicince markets
.Large, Impressive Client Base for Expansion and Cross-selling. VOS’s outstanding reputation with a large customer base and community
of
healthcare professionals offers tremendous expansion and cross-reffering opportunities to accelerate an already very strong market position
One of the Most Successful Regenerative Medicine Companies in the United States in terms of its consistency of results. VOS healthcare has
achieved consistently growing financial metrics for revenues, profits, margins, etc. With a fully post-split diluted EPS of $0.41 for the Q3 of 2011 as
compared to $0.43 in the Q3 of 2010 and $1.51 for the year 2010, VOS has set a very high benchmark for itself. The full year cumulative diluted EPS
for 2010 grew by 47% as
compared to cumulative diluted EPS of $1.03 for the year 2009.
High Growth and Profitable Recurring Revenue Model. With over 75% of its revenue generated from recurring sources, derived from a 99%
plus customer retention rate, VOS has a solid revenue base to build upon affording a high degree of visibility to its growth and future revenues. With
2010 2009 2008 2010 2009 2008
35% revenue 2010 2009 2008 2007 Operating 41% 2009 2008
30% 2007 23% 2006
2010 2009 2008
Margins
growth in 2010 and net income growth of 52% on a year-over-year basis, VOS has continued to post record-setting numbers in terms of income and
Operating Margins 41% 30% 23%
EPS 2011 Q3 Q2 Q1 Q42010
Net income in thousand 42 9 1
$ Consistency of Performance over the last many years. Operating Margins 42% 44% 39% 39%
Growth of 2010 over 52% 116% 365%
other years
Diluted EPS in $ 1.52 1.03 0.36
Q3 2011 Q2 2011 Q1 2011 Q4 2010
Growth of 2010 over 39% 99% 278%
other years
(Diluted earnings per share reflects the 3-for-1 stock split effective January 5, 2010)
6

7. Summary Highlights
Unique Differentiation Enhances VOS Healthcare’s Leadership Opportunity
VOS Healthcare’s exchanges power transactions between hundreds of thousands of patients for these services of stem
cell banking and therapy.
VOS Healthcare’s services extends close to 0.15 million patients every year. VOS Healthcare’s revenue turnaround sums in excess of
$0.5 million in the United States along with overseas business. In Australia the majority of VOS Healthcare work focuses on the Stem
cell Therapy especially on diabetes and cancer treatment. VOS Healthcare’s on-demand Menstrual and Adipose Banking used by
100,000 plus users around the world. With the aggregation of a large community of Stem Cell banking and therapeutics , VOS
Healthcare is seen as a Mentor to Stem Cell markets by these entities. Many Countries are still out of reach of VOS Healthcare
Regenerative Medicine services , gives us a chance to expand and work harder to reach every corner of the globe.
VOS Healthcare has a global reach in Regenerative Medicine knowledge.
VOS Healthcare powers businesses in more than 50 countries today across six continents. VOS Healthcare has a global footprint with
in excess of 10+ offices today world-wide.
VOS Healthcare provides a multi-layer centers(Bud and Root collection center)and advanced lab and research labs with
world-wide quick co-ordination and support, unlike any other player in the regenerative industry that addresses these
markets.
VOS Healthcare systems are multi-lingual, multi-currency and work in French, Portuguese, Spanish, Japanese, Chinese and English.
With fully owned offshore facilities in India, VOS Healthcare has the ability to reduce the cost structure of acquired
companies and increase their efficiency.
VOS Healthcare’s centers in India have Carnegie Mellon’s highest CMMI 5 rating and that establishes the quality of VOS Healthcare’s
operations to any of its prospective customers
Experienced Executive Management Team with Health Expertise and Industry Recognition.
VOS Healthcare’s team includes Physicians, Physician Research, Biotechnologists, Biologist, Nurses and Other accessories Staff with a
deep understanding of the Regenerative Medicine spanning an ample of years of experience amongst them. Its infrastructure and
experienced executive management team is highly capable of sustaining its leadership and developing VOS Healthcare into an even
larger organization.
7

8. Global Footprint
Our markets and our clients cross geographic boundaries. VOS employs hundreds of insurance & technology professionals providin
products, support and consultancy to thousands of customers on six continents across 50+ countries through 30+ offices.
8

9. FINANCIAL SNAPSHOT

10. The Turnaround
! In 2007 VOS Healthcare had $12 Thousand in Net Losses.
! In 2010 VOS had $42.0 Thousand of Net Income.
$42.00
$9.00
$1.00
2010
10

11. Recurring Revenue Streams with
Consistent Growth and Profitability
! 28% revenue growth in Q3 of 2011 as compared to Q3 of 2010 $92.84
! 35% annual revenue growth in 2010 as compared to 2009, 77% as compared to
2008 and 209% as compared to 2007.
! Long-term client relationships with 99.5% retention rates
! Stable, predictable base of recurring revenues
45%
! Approximately 75% plus in recurring revenue streams
! Scaling on-demand model of 40% operating margin levels in 2010
! 52% annual net income growth in 2010 as compared to 2009, 116% as
compared to 2008, 365% as compared to 2007.
$42.84
$24.10
$9.25
$3.75
Revenue Growth & Net Margins (after taxes)
11

12. Recurring Revenue Streams with
Consistent Growth and Profitability
The net income at the end of 2010 grew to $ 42.3 thousand as compared to cumulative net
income of $ 9.4 Thousand at the end of 2009
$1.51
*Diluted earnings per share reflects two 3-for-1
stock splits, namely the 3-for-1 stock split
effective October 9, 2008 and the 3-for-1
stock split effective January 5, 2010
$88.8
2.08
$42.3
$9.4 1.56
$1.3
0.4 1.03
$0.15 $0.21
VOS Net Income Growth & Diluted EPS*
12 A

13. Operating Income and
Operating Cash Flow
Operating Income Quickly grew Realized through Cash Flows
$52.507
Combined Operating Income from 2008-2010 = $0.1 Million
Combined Operating Cash Flows from 2008-2010 = $.4 Million
Realized Operating Cash Flow over 3 yrs. = 300%
$52.779
Operating Income (in thousands)
$39.256
Operating cash flows (in thousands)
$33.877
$12.801
$6.712
$15.039
$4.375
200 2008 2009 2010
7
13

14. Operating Cash Flow
Operating Cash Flow used for:
! Support Organic Growth
! Finance Business Acquisitions $52.779
$51.933
! Re-payment of Debt
! Re-purchase Shares of Common Stock
Operating cash flow (in thousands)
$33.877
$15.039
$4.375
200 2008 2009 2010 YTD 2011
7
14

15. Recurring Income Streams with
Consistent Growth in Margins
Net Income (in millions) $22.30
Operating Margins
$16.70 $16.50
$15.90 $15.20
$14.00
$12.40
44%
42%
40% 40% 39%
39% 39%
Q1-10 Q2-10 Q3-10 Q4-10 Q1-11 Q2-11 Q3-11
VOS Operating Margins & Net Income Growth
15

16. Balance Sheet Metrics
Healthy Balance Sheet with Improving Metrics & Liquidity
Q3 2011 2010 2009 2008
Current Ratio 1.08 1.56 0.62 0.47
Cash Balance (in thousands) $13.941 $23.397 $19.227 $9.475
Working Capital (in thousands) $3.891 $21.697 $(28.582) $(28.330)
Debt/TTM EBITDA 0.35 0.52 0.96 1.53
Debt to equity ratio 0.09 0.15 0.31 0.75
16

17. Balance Sheet
$35.3
Debt $27.2
Dec 31, 2010 - $35.3
Sept 30, 2011 - $27.2
As of As of
Dec 31 2010 Sept 30 2011
2011 Uses of Cash
Share buybacks - $62.7
Extinguishment of Convertible Debt - $6.8
($ in Thousands)
17

18. INDUSTRY AND MARKET OVERVIEW

19. On-Demand Stem Cell Therapy
Industry & Market Overview
Retrieval center
Differentiating Lab
Stem cell Banking Retrieval center Cell culturing
Franchise center Cell preservations
Umbilical cord banking
Sterile collections Cryotherapy
Enrollment
Packaging Sterilization
Collection
Home collections kits Segregation
Processing
Bar-coded labeling Storing
Preservation
Courier Recombinant genetics
Menstrual blood banking
Centrifuging Restructuring
VOS’s footprint addresses Differentiation
Culturing and growing
many of the most strategic requirements
of the Adult
Disease treatment Stem cell therapy industry
Diabetes Research Lab
Liver diseases Global Services Canada
Cardiovascular disorders United states of America
Bone disorder United states of America United Kingdom
Cancer United kingdom Germany
Neuromuscular diseases Poland Poland
Lung disease India Japan
Erectile dysfunction Australia India ( on going)
Anti-ageing & cosmetics
19

20. 21

21. REVENUE DRIVERS & NEW GROWTH INITIATIVES

22. Exchanges Continue to Grow with
Recurring Revenue Streams
Franchise for Franchise for
4% collection
collection
2%
Menstrual blood
Menstrual blood
16% Banking
15%
Banking
11%
22%
Cord Blood banking Cord Blood banking
61% 69%
Adult Stem cell therapy
Adult Stem cell therapy
2010 Q3 2011
23

23. What is Adult Stem cell?
25

24. 26

25. VOS’s Revenue Drivers - Exchange
VOS Exchange
Straight Through Processing
28

26. Brief Biodata of Directors

27. DR Tapan Shah
CEO, VOS Healthcare LLC,
MS, DNB, FaCS, FRCS, MRCP, PhD
Dr.Tapan Shah is founder and CEO of VOS Healthcare LLC, USA, the leading
Regenerative Medicine & Stem Cell Industry on STEM CELL Therapy with a
view to provide the services across Asia Pacific and Europe.
He brings more than 15 years of experience from the Healthcare industry, and
has served in various positions, focusing especially on global marketing and
branding strategy; brand/ product advertising; and corporate communications
Prior to establishing VOS Healthcare LLC, USA, he was Vice President of ReeCell for Ebix Inc, a world
leader in Bioengineering and Biopharma and biotechnology. Based in USA, he being a Liver and
Pancreatic Transplant surgeon along with his dedication towards regenerative medicine, he developed a
core initiation to develop a medical stream to bring disease free world and a cure to all the diseases.
Dr.Tapan Shah was also an account director for ten years with two global healthcare business
Worldwide, where he directed many successful transplant and regenerative programs.
Dr.Tapan Shah is dedicated to sharing his experience with the international audience. He regularly
accepts invitation to chair and speak in top-notched events across Asia and Europe. Recently, he was
appointed chairman of REGER MED2009. He contributes leadership opinion articles on ORGAN
TRANSPLANTATION AND REGENERATIVE MEDICINE issues to international publications.
He is Visiting Professor in Liver Transplantation and Stem cell Center at the UNIVERSITY OF
DRESDEN, GERMANY.

28. Sudha shah
President and CEO, VOS Healthcare Pvt Ltd
Sudha shah is the founding partner, Chief Executive Officer of VOS Healthcare
LLC. VOS provides REGENERATIVE MEDICINE & STEM CELL BANKING and it’s the
only provider for INTERNATIONALLY ACCEPTED stem cell treatment and Banking
not only CORD BLOOD but also Menstrual blood, Adipose Tissues. VOS’ team of
architects and application experts continue to solve complex infrastructure
challenges, helping customers navigate through the convergence of services,
treatment, banking and counseling.
Ms. Shah is responsible for expanding VOS' leadership position in the industry and provides
strategic direction and business development expertise. With a prestigious list of more than
100000 customers and with products deployed all over the globe extending from North America to
Australia, VOS prides itself in understanding and addressing ongoing challenges for its customers by
staying ahead of the technology curve.
She has more than 10 years of Hospital Administration related experience, including strategic
business development, marketing, and product management, bioengineering and patient care and
counseling along with sales for domestic and international markets. Ms. Shah earned lots
of patents during her tenure at Cisco (formerly known as Scientific Atlanta).
She holds a Masters of Commerce degree from The M.S University of Vadodara, Gujarat, India
and a Master of Business Administration Specialization in Hospital Administration from M. S
University.

29. Suresh Nair Profile
Born: March 7, 1976
Achievement: One of the founders of VOS HEALTHCARE LLC, USA;
Suresh Nair is the Non-Executive Chairman and Chief Mentor of VOS
HEALTHCARE LLC. He is an
epitome of the fact that honesty, transparency, and moral integrity are
not at variance with business acumen. He set new standards in corporate
governance and morality.
Born on March 7, 1976, N.R. Suresh Nair is a B.E. Electrical from University of
Vallabh Vidhyanagar and M B A from M.S. University (1969). Suresh Nair began
his career with TCS in Mumbai and later went to Seattle, WA. Later with his
vision for future developed his own company SURAN LLC, USA in Seattle WA. In
2007, Suresh Nair founded VOS HEALTHCARE LLC with two other professionals.
In 2010, VOS HEALTHCARE LLC opened many international office in Poland, UK,
India, Australia.
Along with the growth of VOS Healthcare LLC, USA, Suresh Nair too has grown
in stature. He has received many honours and awards.

30. New Growth Initiatives
Phase I Phase II
Developing Root Developing bud
Labs centers (
franchise)
Phase III
Phase IV
Developing Full
Developing
fledged Lab
Research Lab

31. New Growth Initiatives
Differentiation Labs
INTERFACED
On-Demand
Franchise Stem Cell
Bud collection Therapy Patient Care Executive
INTERFACED INTERFACED
Root collection
INTERFACED
Associated research lab
! Used by BUD Collection center , ROOT Collection center, Review and Ethical Committee, Differentiating Lab, Research Lab
Patient care Executive, Physicians and Social workers, courier, Stem cell Banks
31

32. GROWTH AND FUTURE
EXPANSION POTENTIONAL

33. Adult Stem Cell Therapy- Diabetes
Diabetes affects 25.8 million people of all ages
8.3 percent of the U.S. population
•Among U.S. residents ages 65 years and older, 10.9 million, or 26.9 percent, had
diabetes in 2010.
•About 215,000 people younger than 20 years had diabetes—type 1 or type 2—in the
United States in 2010.
•About 1.9 million people ages 20 years or older were newly diagnosed with diabetes in
2010 in the United States.
•In 2005–2008, based on fasting glucose or hemoglobin A1C (A1C) levels, 35 percent of
U.S. adults ages 20 years or older had pre-diabetes—50 percent of adults ages 65 years
or older.
•U.S. population in 2010 yields an estimated 79 million American adults ages 20 years or
older with pre-diabetes.
•Diabetes is the leading cause of kidney failure, nontraumatic lower-limb
amputations, and new cases of blindness among adults in the United States.
•Diabetes is a major cause of heart disease and stroke.
•Diabetes is the seventh leading cause of death in the United States.

34. Adult Stem Cell Therapy- Liver Disease
•The prevalence of ALD is estimated at >8.4 million people.
•Liver Diseases is the foremost health risk in developing
countries and ranks third in developed countries.
•Liver Diseases caused by ALD, Hepatitis C & B, Other causes
•Only treatment for liver diseases were LIVER
TRANSPLANTATION
•Liver Transplantation is not only very cost but available at very
few centers
•Liver Transplantation is not always possible due to non
availability of organ

35. Adult Stem Cell Therapy-Heart Disease
• 33.5 percent of adults 20 years and older in America have high
blood pressure; 80 percent are aware of their condition but less
than half have their condition under control.
•23.1 percent of men and 18.1 percent of women are cigarette
smokers; 19.5 percent of students in grades 9 through 12 report
current tobacco use.
•15 percent of adults 20 and older have total serum cholesterol
levels of 240 mg/dL or higher.
•8 percent of adults have been diagnosed with diabetes mellitus;
36.8 percent have prediabetes.
•More than 67 percent of adults are overweight.
•During the past 30 years, the prevalence of obesity in children 6
to 11 years has increased from about 4 percent to more than 20
percent

36. Adult Stem Cell Therapy-Cancer
•Cancer rates could further increase by 50% to 15 million new
cases in the year 2020
•malignant tumours were responsible for 12 per cent of the
nearly 56 million deaths worldwide
•The World Cancer Report tells us that cancer rates are set to
increase at an alarming rate globally
• from 10 million new cases globally in 2000, to 15 million in 2020
•About 60 per cent of cases occur in developing countries, with
the highest incidence rates coming in Eastern Asia

37. Adult Stem Cell Therapy- Neurology
•Currently 30 million people with dementia in the world
•13.9% of people aged 71+ are affected by dementia
•Nearly half of people aged 85 and older (43 percent) have Alzheimer’s Disease
•An estimated 5.4 million people have Alzheimer’s disease in USA
•4.6 million new cases annually ( one new case very 7 second)
•Over 100 million people would be affected by 2050
•14.9 million unpaid caregiver
•183 billion dollars in annual costs
•1 in 8 older Americans have ALZHEIMER DISEASE
Prevalence of Parkinson's Disease: 21 million people
Prevalence Rate: approx 1 in 272 or 0.37% or 1 million people
Undiagnosed prevalence of Parkinson's Disease: estimated 3-4 million people
Undiagnosed prevalence rate: approx 1 in 90 or 1.10% or 3 million people
Death rate extrapolations for Parkinson's Disease: 14,593 per year, 1,216 per
month, 280 per week, 39 per day, 1 per hour

38. Adult Stem Cell Therapy- Ortho/ Knee
•13.9% of adults aged 25 + and 33.6% (12.4 million) of those 65+
has OsteoArthritis
•An estimated 41.9 million US adults in 2011 has OA
•Incidence rates increased with age, and level off around age 80.
•Women had higher rates than men, especially after age 50
•$25.9 billion estimated costs of knee and hip replacements in 2011
•Average direct costs of OA ~$9,600 per year out-of-pocket
expenses.
•OA of the knee is 1 of 5 leading causes of disability among non-
institutionalized adults
•80% of patients with OA have some degree of movement
limitation
•25% cannot perform major activities of daily living (ADL’s)
• About 40% of adults with knee OA reported their health “poor”

39. 7 billion customers needs us
• 7 billion
Population • 1 billion Indians
• 1 out of 6 has lethal diseases
Diseases • 1 out of 3 has morbid or lethal diseases
• 1 out of 3 needs stem cell therapy
Stem cell
• If cosmetic/anti-aging included all needs stem
therapy cell therapy

40. New Growth Initiatives - Exchange
FRANCHISE : BUD collection centers
VOS HEALTHCARE ( NaSCFI) Labs is introducing a program by which satellite labs are built in foreign
sites. VOS HEALTHCARE ( NaSCFI) has been producing two types of stem cells from discarded human
umbilical cords(cord blood) AND Adult Stem cells ( adipose, menstrual, neural). These cells have
proven, in international as well as our own experience, to be quite effective and safe in a number of
different health conditions. VOS HEALTHCARE ( NaSCFI) also realizes that having laboratories in
individual states and countries would increase their availability, help more people, avoid the problems
of transportation and importation of such sensitive live cells. In particular, keeping the cells within the
bounds of one state removes jurisdiction from Federal agencies, such as the Food and Drug
Administration and the Federal Trade Commission.
Some desire to establish a stem cell treatment center, as well as the production lab. One lab could
supply many treatment centers. Our intention is to provide labs in individual states, on a first-
come, first-served basis, so that there will not be excessive competition for the existing market. We will
continue a system-wide marketing program, which will provide demand for the product.
Research-level labs will also be available, for an additional cost. These may also be financed by the
same organization. We will have one research lab for each ten production labs. Production labs would
partially support the research labs, and intellectual property would be shared throughout the system.
The above price does not include: full research lab capabilities, vehicles, income or other taxes, back-
up power, or real estate, but does include several months rent or real-estate payments. Real-estate can
also be financed.
Franchisee obligations include assistance with hiring, licensing, coordination with local medical
personnel, including at least one licensed physician to order supplies, procuring a contract for
cords, and local marketing. Franchisee will also provide a 10% licensing fee for each stem cell unit sold.
Lab is designed to fit in a 700 ft2 office or lab space
Projected profits operating at a low level (2 cords per day) would yield over $1 million yearly, and
expansion up to 8 cords per day ($5 M per year) could be done with this lab.
32

41. New Growth Initiatives
Stem Cell Banking
Fixed deposit of health
Premium of life insurance
Pension your Health Guard
Stem cell Banking
Cord blood banking Other Stem cell banking
•A Menstrual blood stem cell
•cGTP & c GMP accredited labs •first of its kind in India with international standard
•Precious gift given to every new born •normally discarded as unsanitary waste, is now a boon
•properties and characteristics similar to both bone marrow and
•Cord and placental banking possible embryonic stem cells.
•Collections network all across gynec hospitals •easily collected with painless and non-invasive procedures
•Highest sterility techniques ( rated best) •processed and harvested at affordable rates.
•Easily collected and handled Adipose stem cell banking
•Helps treating many early age diseases •Adipose (fat) tissue is found throughout body.
•ability to differentiate into bone, muscle, fat, nerve, and cartilage.
•Higher viable stem cell •obtain through a simple and localized liposuction process
•Banking near airport, so quick response •Adipose-derived stem cells are easy to obtain thro liposuction
•same morphology, immune phenotype and differentiation capacity
•free of ethical debate /abundant and easy to access.
•yield more than 200 million stem cells of which 95% are mesenchymal
stem cells.
•cryopreservation: for almost 25 years
34

42. VOS’s Revenue Drivers - Exchange
Advance labs and Regenerative Medicine 2010 - 12% Q3 2011 - 8%
Percentage of Total Revenue
•Advance lab
•Culturing
•Sterilization
•Cell counting
•Stimulation
Advance labs and
•Cyro preservation
Research labs
•Differentiation and growth
•Newer source of stem cell
•Newer means of delivering
•Local patches and oral delivery
•Biopharma
•More viability and efficacy
35

43. VOS’s Revenue Drivers
The healthcare Channel 2010 - 10% Q3 2011 - 11%
Percentage of Total Revenue
•Self manageable kits •Coordination with patients and bud centers
•Adequate education •Cohesively work with root centers
•Door step collection and counselling •Patient counseling
•Online consultation
•No OPD policy •Marketing and media conferencing
•Mass awareness activity •Corporate liaisioning
•24*7 helpline •Packaging and Culturing
•Ethical committee
•Review committee •Achieves handling
•Finance availability •Labeling and forwarding
•Special package for corporate Patients Center
groups
Lab
BUD collection center
Root collection center
Advance lab
Research lab
37

44. Acquisitions
!Marketplace remains robust
!Constantly evaluating companies
!Prices coming down
Criteria
!Accretive to earnings in 90-180 days
!Adds to our Customer base
!Adds to our Product base
!70% or more of recurring revenue
!Service On-Demand a must
!Low customer attrition rates
!Complements our existing product base
38

45. Understanding of Competitive Edge
The Secret Mantra
Cost Price Selling Price
Key Company Goals: Operating Margins of 40% or more
On Demand Banking and Franchise generating revenue str
39

46. Summary
! First mover advantage in our markets
! Large untapped market potential
! Minimal customer attrition
!75% plus recurring revenues
! Sustainable 40% operating margins
! Strong free cash flow generation
! Minimal debt
! Chairman owns 20% of the company
40

47. THANK YOU